Cellosaurus logo
expasy logo

Cellosaurus ARH-77 (CVCL_1072)

[Text version]
Cell line name ARH-77
Synonyms ARH 77; ARH77
Accession CVCL_1072
Resource Identification Initiative To cite this cell line use: ARH-77 (RRID:CVCL_1072)
Comments Problematic cell line: Misclassified. Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=4042077; PubMed=7579375; PubMed=10516762).
Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: 110.4 hours (PubMed=566614); ~30 hours (DSMZ=ACC-512).
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
Omics: Array-based CGH.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Misspelling: AHR 77; Note=Occasionally.
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Cell type: B-cell; CL=CL_0000236.
Sequence variations
  • Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (Cosmic-CLP=906765).
Genome ancestry Source: PubMed=30894373

Origin% genome
African2.24
Native American0.38
East Asian, North0
East Asian, South2.18
South Asian8.63
European, North25.32
European, South61.25
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_A5YK (ARH-77 clone A5P3)CVCL_8119 (HMy.2 B)
Sex of cell Female
Age at sampling 33Y
Category Transformed cell line
STR profile Source(s): ATCC=CRL-1621; CLS=300306; Cosmic-CLP=906765; DSMZ=ACC-512; ECACC=88121201

Markers:
AmelogeninX
CSF1PO6,10
D2S133817
D3S135816
D5S81810,13
D6S104311,19
D7S8207,12
D8S117914,15
D12S39119,20
D13S31711,13
D16S5399,13
D18S5114,16
D19S43314,15
D21S1129,30
FGA20,21
Penta D10
Penta E12
TH018,9.3
TPOX8
vWA17

Run an STR similarity search on this cell line
Web pages https://www.atcc.org/en/support/technical-support/faqs/normal-morphology-for-atcc-crl-1621
Publications

PubMed=566614
Burk K.H., Drewinko B., Trujillo J.M., Ahearn M.J.
Establishment of a human plasma cell line in vitro.
Cancer Res. 38:2508-2513(1978)

PubMed=7140810; DOI=10.1002/eji.1830120804
Edwards P.A.W., Smith C.M., Neville A.M., O'Hare M.J.
A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line.
Eur. J. Immunol. 12:641-648(1982)

PubMed=6605913; DOI=10.1016/0165-2478(83)90049-4
Ralph P., Saiki O., Maurer D.H., Welte K.
IgM and IgG secretion in human B-cell lines regulated by B-cell-inducing factors (BIF) and phorbol ester.
Immunol. Lett. 7:17-23(1983)

PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- 1 carboxylic esterase.
Leuk. Res. 9:209-229(1985)

PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cell lines -- III Beta-hexosaminidase (E.C. 3.2.1.30).
Leuk. Res. 9:549-559(1985)

PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x
Drexler H.G., Gaedicke G., Minowada J.
Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.
Leuk. Res. 9:537-548(1985)

PubMed=4042077; DOI=10.1002/1097-0142(19851115)56:10<2544::AID-CNCR2820561039>3.0.CO;2-g
Ralph P.
The human B-cell lineage cell line ARH-77.
Cancer 56:2544-2545(1985)

Patent=US4730036
Ralph P., Welte K.
Purifications of B-cell inducing factor (BIF) and B-cell growth factor (BGF).
Patent number US4730036, 08-Mar-1988

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=8051085; DOI=10.1016/S0021-9258(17)32120-8
Liebersbach B.F., Sanderson R.D.
Expression of syndecan-1 inhibits cell invasion into type I collagen.
J. Biol. Chem. 269:20013-20019(1994)

PubMed=7579375; DOI=10.1182/blood.V86.10.4001.bloodjournal86104001
Pellat-Deceunynck C., Amiot M., Bataille F.-R., Van Riet I., Van Camp B., Omede P., Boccadoro M.
Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after.
Blood 86:4001-4002(1995)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x; PMCID=PMC5921588
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=10516762; DOI=10.1038/sj.leu.2401510
Drexler H.G., Dirks W.G., MacLeod R.A.F.
False human hematopoietic cell lines: cross-contaminations and misinterpretations.
Leukemia 13:1601-1607(1999)

DOI=10.1007/0-306-46877-8_4
Jernberg-Wiklund H., Nilsson K.
Multiple myeloma cell lines.
(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000)

PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2
Drexler H.G., Matsuo Y.
Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.
Leuk. Res. 24:681-703(2000)

PubMed=14555701
Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D., Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.
Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
Mol. Cancer Ther. 2:825-833(2003)

PubMed=18262052; DOI=10.1016/j.cancergencyto.2007.10.013
Parker H., Cheung K.L., Robinson H.M., Harrison C.J., Strefford J.C.
Cytogenetic and genomic characterization of cell line ARH77.
Cancer Genet. Cytogenet. 181:40-45(2008)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767; PMCID=PMC2861168
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)

Cross-references
Cell line collections (Providers) ATCC; CRL-1621
BCRC; 60385
CCTCC; GDC0218
CLS; 300306
DSMZ; ACC-512
ECACC; 88121201
Cell line databases/resources CLO; CLO_0001744
CLO; CLO_0001745
CLDB; cl285
CCRID; 4201HUM-CCTCC00218
Cell_Model_Passport; SIDM00900
Cosmic-CLP; 906765
DepMap; ACH-002210
DSMZCellDive; ACC-512
IGRhCellID; ARH77
LINCS_LDP; LCL-2041
Lonza; 593
Anatomy/cell type resources BTO; BTO_0002992
Biological sample resources BioSample; SAMN03471407
CRISP screens repositories BioGRID_ORCS_Cell_line; 831
Chemistry resources ChEMBL-Cells; CHEMBL3308536
ChEMBL-Targets; CHEMBL2366241
GDSC; 906765
PharmacoDB; ARH77_64_2019
PubChem_Cell_line; CVCL_1072
Encyclopedic resources Wikidata; Q54750440
Experimental variables resources EFO; EFO_0002111
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-3610
GEO; GSM1374393
GEO; GSM1669601
Polymorphism and mutation databases Cosmic; 759914
Cosmic; 886086
Cosmic; 888020
Cosmic; 906765
Cosmic; 919148
Cosmic; 999792
IARC_TP53; 21176
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation04-Apr-2012
Last entry update19-Dec-2024
Version number42